002365SZSE

Q1 Report for 2026

✨ AI Summary

This announcement presents the Q1 2026 financial report of Qianjiang Yong'an Pharmaceutical Co., Ltd. The company reported a 37.83% increase in revenue to approximately CNY 235.9 million and a net profit attributable to shareholders of CNY 7.74 million, a significant turnaround from a loss in the previous year. The report also highlights a negative cash flow from operating activities and outlines key changes in financial metrics and shareholder information.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Important Content Reminder

  1. The board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, and assume individual and joint legal responsibilities.
  2. The person in charge of the company, the head of accounting, and the accounting institution declare that they ensure the financial information in the quarterly report is true, accurate, and complete.
  3. The quarterly financial report has not been audited.

Main Financial Data

(1) Key Accounting Data and Financial Indicators

The company does not need to restate or adjust previous years' accounting data.

ItemCurrent PeriodSame Period Last YearChange (%)
Operating Revenue (CNY)235,897,297.00171,153,602.9637.83%
Net Profit Attributable to Shareholders (CNY)7,736,703.46-4,367,181.24277.16%
Net Profit Attributable to Shareholders after Non-recurring Gains and Losses (CNY)7,250,939.13-6,669,596.75208.72%
Net Cash Flow from Operating Activities (CNY)-1,431,776.2724,701,934.36-105.80%
Basic Earnings per Share (CNY/share)0.0268-0.0151277.48%
Diluted Earnings per Share (CNY/share)0.0268-0.0151277.48%
Weighted Average Return on Equity0.39%-0.22%0.61%

(2) Non-recurring Gains and Losses

ItemAmount for Current Period (CNY)Description
Loss from Disposal of Non-current Assets-33,352.93
Government Subsidies Recognized in Current Period647,764.19
Fair Value Changes of Financial Assets892,253.69
Other Income and Expenses-995,997.58
Less: Income Tax Impact21,862.21
Minority Interests Impact (after tax)3,040.83
Total485,764.33

(3) Changes in Key Accounting Data and Financial Indicators

ItemEnd of Period BalanceBeginning of Period BalanceChange AmountChange RatioMain Reasons for Change
Notes Receivable1,300,077.975,980,717.37-4,680,639.40-78.26%Mainly due to endorsement transfer and maturity of notes.
Accounts Receivable153,588,084.52116,835,678.9236,752,405.6031.46%Mainly due to increased product sales during the reporting period.
Financing Receivables7,958,428.982,152,013.645,806,415.34269.81%Mainly due to increased bank acceptance bills received.
Prepayments12,850,450.838,813,805.834,036,645.0045.80%Mainly due to increased prepayments by subsidiaries.
Other Receivables3,110,307.065,437,851.15-2,327,544.09-42.80%Mainly due to receipt of export tax rebates.
Construction in Progress53,724,370.5718,900,382.6434,823,987.93184.25%Mainly due to increased investment in subsidiary projects.
Other Non-current Assets3,717,269.806,547,752.02-2,830,482.22-43.23%Mainly due to settlement of engineering-related bills.
Other Current Liabilities5,654,234.5211,583,781.54-5,929,547.02-51.19%Mainly due to decreased endorsed but unexpired acceptance bills at the end of the reporting period.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.